228 related articles for article (PubMed ID: 31970629)
1. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
Nakamura M; Kanda S; Yoshioka Y; Takahashi C; Owada K; Kajiho Y; Harita Y; Oka A
CEN Case Rep; 2020 May; 9(2):173-176. PubMed ID: 31970629
[TBL] [Abstract][Full Text] [Related]
2. The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies.
Sato M; Yamada M; Nakajima M; Miyama Y; Kitayama H
CEN Case Rep; 2020 Nov; 9(4):392-394. PubMed ID: 32535844
[TBL] [Abstract][Full Text] [Related]
3. Serum sickness with refractory nephrotic syndrome following treatment with rituximab.
Maeda R; Kawasaki Y; Ohara S; Suyama K; Hosoya M
CEN Case Rep; 2018 May; 7(1):69-72. PubMed ID: 29305810
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-induced serum sickness in a girl with nephrotic syndrome.
Kimura Y; Kiyota K; Ikeuchi M; Sekiguchi K; Ihara K
CEN Case Rep; 2022 Nov; 11(4):506-510. PubMed ID: 35596114
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome.
Bayram MT; Soylu A; Kavukçu S
Turk J Pediatr; 2020; 62(5):884-888. PubMed ID: 33108096
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
10. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
11. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
12. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
13. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.
Sato M; Ito S; Ogura M; Kamei K
Pediatr Nephrol; 2014 Aug; 29(8):1373-9. PubMed ID: 24599443
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of nephrotic syndrome: a systematic review.
Otukesh H; Hoseini R; Rahimzadeh N; Fazel M
Iran J Kidney Dis; 2013 Jul; 7(4):249-56. PubMed ID: 23880800
[TBL] [Abstract][Full Text] [Related]
17. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.
Sinha A; Mathew G; Arushi A; Govindarajan S; Ghanapriya K; Grewal N; Rai K; Brijwal M; Kalluru SL; Tewari P; Misra A; Khandelwal P; Hari P; Bagga A
Nephrol Dial Transplant; 2023 Mar; 38(4):939-949. PubMed ID: 36071552
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
Morita K; Shibano T; Maekawa K; Hattori M; Hida N; Nakamura S; Takeshima Y
CEN Case Rep; 2019 Feb; 8(1):55-60. PubMed ID: 30251194
[TBL] [Abstract][Full Text] [Related]
19. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
Takahashi T; Okamoto T; Sato Y; Yamazaki T; Hayashi A; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T
Pediatr Nephrol; 2019 Jan; 34(1):87-96. PubMed ID: 30141179
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study.
Bayer G; Agier MS; Lioger B; Lepelley M; Zenut M; Lanoue MC; Maillot F; Jonville-Bera AP
Eur J Intern Med; 2019 Sep; 67():59-64. PubMed ID: 31279430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
